A Phase II Study of L-BLP25 and Bevacizumab in Unresectable Stage IIIA and IIIB Non-Squamous Non-Small Cell Lung Cancer After Definitive Chemoradiation
The purpose of this study is to find out what effects, good and/or bad, the addition of L-BLP25 vaccine and bevacizumab to the commonly used treatment of paclitaxel, carboplatin, and thoracic radiation therapy (radiation to the chest) has on lung cancer. This research is being done because we want to see if the investigational drug L-BLP25 with bevacizumab will improve on the results of the standard treatment with paclitaxel and carboplatin. L-BLP25 may help to slow or stop the cancer cells from growing by helping the body to boost the immune system that is used to fight disease. Bevacizumab works by slowing or stopping the growth of blood vessels into tumors. Tumors need blood vessels in order to grow.
Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.
- biological : emepepimut-S
- biological : bevacizumab
- drug : paclitaxel
- drug : carboplatin
- drug : cyclophosphamide
- radiation : radiation therapy
Phase: Phase 2
Ages Eligible For Study: